Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality

Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

(2021) · doi:10.1101/2021.03.01.433466 · Cited by 626

Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases

Rabinowitz, K. M., Navon, M., Edelman-Klapper, H., Zittan, E., Shitrit, A. B., Goren, I., Avni‐Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., et al. (2022) · Vaccines · doi:10.3390/vaccines10081186 · Cited by 18

Durability analysis of the highly effective BNT162b2 vaccine against COVID-19

Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Niesen, M. J. M., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Gordon, J. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac082 · Cited by 16

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Christensen, I. E., Jyssum, I., Tveter, A. T., Sexton, J., Tran, T. T., Mjaaland, S., Kro, G. B., Kvien, T. K., Warren, D. J., Jahnsen, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02587-8 · Cited by 18

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in AdolescentsPreprint

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · medRxiv · doi:10.1101/2022.01.04.22268776 · Cited by 16

Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory

Bai, J., Chiba, A., Murayama, G., Kuga, T., Yahagi, Y., Tabe, Y., Tamura, N., & Miyake, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-24938-4 · Cited by 17

Great Expectations of COVID-19 Herd Immunity

Giurgea, L. T., & Morens, D. M. (2022) · mBio · doi:10.1128/mbio.03495-21 · Cited by 15

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques

Zabaleta, N., Bhatt, U., Hérate, C., Maisonnasse, P., Sanmiguel, J. C., Diop, C. T., Castore, S., Estelien, R., Li, D., Dereuddre‐Bosquet, N., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.007 · Cited by 17

Integrative systems immunology uncovers molecular networks of the cell cycle that stratify COVID‐19 severity

Prado, C. A. D. S., Fonseca, D. L. M., Singh, Y., Filgueiras, I. S., Baiocchi, G. C., Plaça, D. R., Marques, A. H. C., Dantas‐Komatsu, R. C. S., Usuda, J. N., Freire, P. P., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28450 · Cited by 13

Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization

Jiang, W., Maldeney, A. R., Yuan, X., Richer, M. J., Renshaw, S. E., & Luo, W. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113665 · Cited by 16

Going Online?—Can Online Exercise Classes during COVID-19-Related Lockdowns Replace in-Person Offers?

Füzéki, E., Schröder, J., Reer, R., Groneberg, D. A., & Banzer, W. E. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19041942 · Cited by 14

SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination

Peter, J. K., Wegner, F., Gsponer, S., Helfenstein, F., Roloff, T. C., Tarnutzer, R., Grosheintz, K., Back, M., Schaubhut, C., Wagner, S., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10050857 · Cited by 12

Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation

Breskin, A., Wiener, C., Adimora, A. A., Brown, R. S., Landis, C. S., Reddy, K. R., Verna, E. C., Crawford, J. M., Mospan, A. R., Fried, M. W., et al. (2023) · Epidemiology · doi:10.1097/ede.0000000000001598 · Cited by 14

An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding

Blumenthal, K. G., Greenhawt, M., Phillips, E. J., Agmon‐Levin, N., Golden, D. B. K., & Shaker, M. S. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.06.057 · Cited by 12

Determining the Reliability of Rapid SARS-CoV-2 Antigen Detection in Fully Vaccinated Individuals

Poopalasingam, N., Korenkov, M., Ashurov, A., Strobel, J., Fish, I., Hellmich, M., Gruell, H., Lehmann, C., Heger, E., & Klein, F. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105119 · Cited by 15

Conservation and Evolution of Antigenic Determinants of SARS-CoV-2: An Insight for Immune Escape and Vaccine Design

Jaiswal, V., & Lee, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832106 · Cited by 13

Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection

Épaulard, O., Abgrall, S., Lefebvre, M., Faucher, J., Michon, J., Frentiu, E., Blanchi, S., Janssen, C., Charbonnier, G., Fresse, A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.06.019 · Cited by 12

Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents

Patalon, T., Saciuk, Y., Hadad, H. O., Peretz, A., Peretz, A., Ben‐Tov, A., & Gazit, S. (2023) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2023.02.016 · Cited by 13

Finger stick blood test to assess postvaccination SARS‐CoV ‐2 neutralizing antibody response against variants

Lim, S. M., Cheng, H. L., Jia, H., Kongsuphol, P., Shunmuganathan, B. D. O., Chen, M. W., Ng, S. Y., Gao, X., Turaga, S. P., Heussler, S. P., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10293 · Cited by 12

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11

Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course

Swadźba, J., Anyszek, T., Panek, A., Chojęta, A., Wyrzykowska, K., & Martin, E. (2022) · Diagnostics · doi:10.3390/diagnostics12061426 · Cited by 12

Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries

Bert, F., Scaioli, G., Vola, L., Accortanzo, D., Moro, G. L., & Siliquini, R. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127233 · Cited by 15

COVID‐19 vaccine effectiveness against hospitalization due to SARS‐CoV‐2: A test‐negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain

Mazagatos, C., Delgado‐Sanz, C., Monge, S., Pozo, F., Oliva, J. A., Sandonis, V., Gandarillas, A., Rubio, C. Q., Ruiz‐Sopeña, C., García, V. G., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13026 · Cited by 12

Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic

Sun, Y., Luo, B., Liu, Y., Wu, Y., & Chen, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130398 · Cited by 13

Modeling SARS‐CoV‐2 True Infections in Catalonia through a Digital Twin

Casas, P. F. I., Subirana, J. G. I., & Carrasco, V. G. I. (2023) · Advanced Theory and Simulations · doi:10.1002/adts.202200917 · Cited by 12

High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge

Ujjainiya, R., Tyagi, A., Sardana, V., Naushin, S., Bhatheja, N., Kumar, K., Barman, J., Prakash, S., Kutum, R., Bhaskar, A. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29404-3 · Cited by 10

Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England

Andrews, N. J., Stowe, J., Kirsebom, F. C. M., Toffa, S., Sachdeva, R., Gower, C., Ramsay, M. E., & Bernal, J. L. (2022) · Nature Medicine · doi:10.1038/d41591-022-00013-3 · Cited by 11

How many lives do COVID vaccines save? Evidence from Israel

Arbel, R., Moore, C. M., Sergienko, R., & Pliskin, J. S. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.12.019 · Cited by 11

Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan

Jamal, Z., Haider, M., Ikram, A., Salman, M., Rana, M. S., Rehman, Z., Haider, S. A., Ammar, M., Nisar, N., & Umair, M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.987452 · Cited by 10

Willingness to receive COVID‐19 booster dose and its associated factors in Ghana: A cross‐sectional study

Storph, R. P., Essuman, M. A., Duku‐Takyi, R., Akotua, A., Asante, S., Armah, R., Donkoh, I. E., & Addo, P. A. (2023) · Health Science Reports · doi:10.1002/hsr2.1203 · Cited by 10

Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test

Wang, Q., Feng, L., Zhang, H., Gao, J., Mao, C., Landesman‐Bollag, E., Mostoslavsky, G., Lunderberg, J. M., Zheng, W., Hao, S., et al. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac004 · Cited by 11

VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern

O’Donnell, K. L., Gourdine, T., Fletcher, P., Shifflett, K., Furuyama, W., Clancy, C. S., & Marzi, A. (2022) · Vaccines · doi:10.3390/vaccines10030435 · Cited by 8

Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France

Decarreaux, D., Pouquet, M., Souty, C., Vilcu, A., Prévot-Monsacre, P., Fourié, T., Villarroel, P. M. S., Priet, S., Blanché, H., Sébaoun, J.-M., et al. (2022) · Viruses · doi:10.3390/v14050957 · Cited by 10

Dynamics in COVID-19 symptoms during different waves of the pandemic among children infected with SARS-CoV-2 in the ambulatory setting

Ben‐Tov, A., Lotan, R., Gazit, S., Chodick, G., Perez, G., Mizrahi-Reuveni, M., & Patalon, T. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04531-7 · Cited by 11

Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022

Seekircher, L., Siller, A., Astl, M., Tschiderer, L., Wachter, G. A., Pfeifer, B. E., Huber, A., Gaber, M., Schennach, H., & Willeit, P. (2022) · Viruses · doi:10.3390/v14091877 · Cited by 10

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

Neuhann, J., Stemler, J., Carcas, A. J., Frías, J., Bethe, U., Heringer, S., Tischmann, L., Zarrouk, M., Cüppers, A., König, F., et al. (2022) · Trials · doi:10.1186/s13063-022-06791-y · Cited by 10

Decoupling between SARS-CoV-2 transmissibility and population mobility associated with increasing immunity from vaccination and infection in South America

Fiori, M., Bello, G., Wschebor, N., Lecumberry, F., Ferragut, A., & Mordecki, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-10896-4 · Cited by 10

COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants

Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10

Demographic Differences in Compliance with COVID-19 Vaccination Timing and Completion Guidelines in the United States

Zhu, P., Zhang, V., & Wagner, A. L. (2023) · Vaccines · doi:10.3390/vaccines11020369 · Cited by 10

Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough InfectionPreprint

Evans, J. P., Zeng, C., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J., & Liu, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.06.471455 · Cited by 10

Universal whole-genome Oxford nanopore sequencing of SARS-CoV-2 using tiled amplicons

Kalendar, R. N., Kairov, U., Karabayev, D., Aitkulova, A. M., Tynyshtykbayeva, N., Daniyarov, A. Z., Otarbay, Z., Rakhimova, S., Akilzhanova, A. R., & Sarbassov, D. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-37588-x · Cited by 9

Incidence of Positive Severe Acute Respiratory Syndrome Coronavirus Polymerase Chain Reaction After Coronavirus Disease 2019 Vaccination With up to 8 Months of Follow-up: Real-life Data From the Capital Region of Denmark

Heftdal, L. D., Schultz, M., Lange, T., Knudsen, A. D., Fogh, K., Hasselbalch, R. B., Linander, C. B., Kallemose, T., Bundgaard, H., Grønbæk, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac012 · Cited by 9

Long‐term immunity in convalescent Syrian hamsters provides protection against new‐variant SARS‐CoV‐2 infection of the lower but not upper respiratory tract

Stauft, C. B., Selvaraj, P., Lien, C. Z., Starost, M. F., & Wang, T. T. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27641 · Cited by 9

Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers

Assaid, N., Arich, S., Charoute, H., Akarid, K., Ezzikouri, S., Maaroufi, A., & Sarih, M. (2022) · Vaccines · doi:10.3390/vaccines10030465 · Cited by 12

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with CLL during the Omicron Surge

Tadmor, T., Alapi, H., & Rokach, L. (2023) · Blood · doi:10.1182/blood.2022019017 · Cited by 9

COVID-19 outcome trends by vaccination status in Canada, December 2020–January 2022

Dam, D., Merali, S., Chen, M., Coulby, C., Fane, B. H. M., Bang, F., Robson, J., & David, S. (2024) · Canada Communicable Disease Report · doi:10.14745/ccdr.v50i12a05 · Cited by 11

Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine

Brill, L., Rechtman, A., Shifrin, A., Rozenberg, A., Afanasiev, S., Zveik, O., Haham, N., Levin, N., & Vaknin‐Dembinsky, A. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103863 · Cited by 9

Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021

Marrone, G., Nicolay, N., Bundle, N., Karki, T., Spiteri, G., Suija, H., Kärblane, K.-G., Mossong, J., Vergison, A., Avdicova, M., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.7.2200060 · Cited by 8

Elucidating Atomistic Insight into the Dynamical Responses of the SARS-CoV-2 Main Protease for the Binding of Remdesivir Analogues: Leveraging Molecular Mechanics To Decode the Inhibition Mechanism

Samanta, P. N., Majumdar, D., & Leszczyński, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00105 · Cited by 8

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Dedroogh, S., Schmiedl, S., Thürmann, P., Graf, K., Appelbaum, S., Koß, R., Theis, C., Zia, Z., Tebbenjohanns, J., Thal, S. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-34961-8 · Cited by 11

Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence

Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 9

A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales

Serisier, A., Beale, S., Boukari, Y., Hoskins, S., Nguyen, V. G., Byrne, T., Fong, W. L. E., Fragaszy, E., Geismar, C., Kovar, J., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.073 · Cited by 7

An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines

Kale, A., Gaur, A., Menon, I., Chirmule, N. B., Bagwe, P., Jawa, R., Vijayanand, S., Patil, S., Suresh, S., & Jawa, V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.01.019 · Cited by 8

Antibody response to the third dose of inactivated COVID‐19 vaccine in people living with HIV (PLWH): A longitudinal cohort

Zeng, G., He, F., Zhang, X., Li, G., Wang, X., Gan, Y., Zheng, C., Tang, J., Xu, L., Zhao, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28797 · Cited by 8

How do state authorities act under existential uncertainty? Hypotheses on the social logic of political decision-making processes during the Coronavirus pandemic

Kraemer, K. (2022) · Culture Practice & Europeanization · doi:10.5771/2566-7742-2022-1-5 · Cited by 7

Temporal Trend of COVID-19 Vaccine Acceptance and Factors Influencing International Travellers

Onwan, M., Matsee, W., Lawpoolsri, S., Pisutsan, P., Siripoon, T., Punrin, S., & Piyaphanee, W. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7090223 · Cited by 7

Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing

Gillot, C., Bayart, J., Closset, M., Cabo, J., Maloteau, V., Dogné, J., Douxfils, J., & Favresse, J. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0134 · Cited by 9

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02167-z · Cited by 7

SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review

Jing, X., Han, M., Wang, X., & Zhou, L. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08553-w · Cited by 9

Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study

David, S. S. B., Mizrahi, B., Rahamim‐Cohen, D., Supino‐Rosin, L., Shahar, A., Alon, S. H., Sacerdote, A. F., Irony, A., Lazar, R., Kalkstein, N., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.051 · Cited by 7

Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients Who Were Either Fully Vaccinated with Coronavac or Not: An Analytical, Cross Sectional Study

Yavuz, S. Ş., Tunçer, G., Aydın, Ö. A., Aydın, M., Pehlıvanoglu, F., Tok, Y., Meşe, S., Gündüz, A., Geyiktepe-Güçlü, C., Özdoğan, İ., et al. (2022) · Vaccines · doi:10.3390/vaccines10050733 · Cited by 7

Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study

Brosh‐Nissimov, T., Maor‬‏, ‪., Elbaz, M., Lipman‐Arens, S., Weil‐Weiner, Y., Hussein, K., Orenbuch‐Harroch, E., Cohen, R., Zimhony, O., Chazan, B., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.20.2101026 · Cited by 7

Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff

Gallichotte, E. N., Nehring, M., Stromberg, S., Young, M. C., Snell, A., Daniels, J., Pabilonia, K. L., VandeWoude, S., Ehrhart, N. P., & Ebel, G. D. (2022) · mSphere · doi:10.1128/msphere.00169-22 · Cited by 7

Knowledge, perception, and acceptance toward the booster dose of COVID-19 vaccine among patients visiting dental clinics in Aseer region of KSA

Abullais, S. S., Arora, S., Alshahrani, M. S., Khan, A. A., Shahrani, W. A., Mahmood, S. E., Qahtani, S. A., Maqbool, M., Jameel, A. S., & Saluja, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2095162 · Cited by 6

The role of Israeli researchers in the scientific literature regarding COVID-19 vaccines

Rosen, B., Davidovitch, N., Chodick, G., & Israeli, A. (2022) · Israel Journal of Health Policy Research · doi:10.1186/s13584-022-00548-3 · Cited by 7

In situ preparation of water-stable SiO2@mSiO2/CsPbBr3 and its application in WLED

Xia, H., Wang, L., Ding, H., Hu, B., Li, Q., Li, H., Yu, T., Liu, Z., Tian, F., & Jin, L. (2024) · Journal of Alloys and Compounds · doi:10.1016/j.jallcom.2024.174322 · Cited by 6

Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants

Lunderberg, J. M., Dutta, S., Collier, A.-R. Y., Lee, J.-S., Hsu, Y., Wang, Q., Zheng, W., Hao, S., Zhang, H., Feng, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032574 · Cited by 7

The Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf): Risk Factors and Determinants of Immune Response in Healthcare Workers

Reinkemeyer, C., Khazaei, Y., Weigert, M., Hannes, M., Gleut, R. L., Plank, M., Winter, S., Noreña, I., Meier, T., Xu, L., et al. (2023) · Viruses · doi:10.3390/v15071574 · Cited by 6

Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers

Syrimi, N., Sourri, F., Giannakopoulou, M.-C., Karamanis, D., Pantousas, A., Georgota, P., Rokka, E., Vladeni, Z., Tsiantoula, E., Soukara, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093172 · Cited by 5

Breakthrough Infections: Clinical Profile and Outcomes of COVID-19 Vaccinated and Unvaccinated People From a Tertiary Care Hospital

Shahapur, P. R., Shahapur, R. P., Bagali, S., Karigoudar, R. M., Wavare, S. M., Jyothi, P. P., Kandi, V., Suvvari, T. K., Mittal, R. J., & Jadhav, M. (2022) · Cureus · doi:10.7759/cureus.32089 · Cited by 5

Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2–inactivated vaccine

He, X., Cao, Y., Lu, Y., Qi, F., Wang, H., Liao, X., Xu, G., Yang, B., Ma, J., Li, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181121 · Cited by 5

Potential Effects of Iodine Supplementation on Inflammatory Processes and Toxin Removal Following COVID-19 Vaccination

Boretti, A. A., & Banik, B. K. (2021) · Biological Trace Element Research · doi:10.1007/s12011-021-02996-5 · Cited by 5

Vaccine breakthrough infections in a highly-vaccinated Australian population during a SARS-CoV-2 Delta outbreak

Sheel, M., Voo, T. V., Pingault, N. M., Sloan-Gardner, T., Marmor, A., Kirk, M., Johnston, V., & Coleman, K. (2022) · Communicable Diseases Intelligence · doi:10.33321/cdi.2022.46.32 · Cited by 5

Modeling Incorporating the Severity-Reducing Long-term Immunity: Higher Viral Transmission Paradoxically Reduces Severe COVID-19 During Endemic Transition

Hong, H., Noh, J. Y., Lee, H., Choi, S., Choi, B., Kim, J. K., & Shin, E. (2022) · Immune Network · doi:10.4110/in.2022.22.e23 · Cited by 5

Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study

Tanır, F., Mete, B., Demırhındı, H., Kara, E., Nazlıcan, E., Dağlıoğlu, G., Kibar, F., Çetiner, S., & Kanat, C. (2022) · Vaccines · doi:10.3390/vaccines10081177 · Cited by 6

Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2

Bannick, M. S., Gao, F., Brown, E. R., & Janes, H. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad046 · Cited by 5

What pushed Israel out of herd immunity? Modeling COVID-19 spread of Delta and Waning immunityPreprint

De-Leon, H., & Aran, D. (2021) · medRxiv · doi:10.1101/2021.09.12.21263451 · Cited by 5

Identification of dynamic gene expression profiles during sequential vaccination with ChAdOx1/BNT162b2 using machine learning methods

Li, J., Ren, J., Liao, H., Guo, W., Feng, K., Huang, T., & Cai, Y. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1138674 · Cited by 5

The humoral response to COVID-19 vaccinations can predict the booster effect on health care workers—toward personalized vaccinations?

Freund, O., Harish, A., Breslavsky, A., Wand, O., Zacks, N., Bilenko, N., & Bar‐Shai, A. (2023) · Journal of Public Health · doi:10.1093/pubmed/fdad198 · Cited by 4

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination

Kim, A., Kim, S., Song, J.-E., Hwang, S., Nam, E., & Kwon, K. T. (2023) · Vaccines · doi:10.3390/vaccines11020363 · Cited by 5

Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients

Moal, V., Valade, M., Boschi, C., Robert, T., Orain, N., Bancod, A., Edouard, S., Colson, P., & Scola, B. L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1147455 · Cited by 4

National epidemiological analysis of the association of COVID-19 vaccination and incidence of COVID-19 cases in Canada, January to August 2021

Coverage, V., System, I., & Surveillance, V. E. (2023) · Canada Communicable Disease Report · doi:10.14745/ccdr.v49i04a07 · Cited by 4

Increased incidence of COVID‐19 in younger patients (May–July 2021)—An argument for extending vaccination?

Bird, P. W., Riff, R., Folwell, A., Holmes, C. W., & Tang, J. W.-T. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27363 · Cited by 4

Vaccine Effectiveness Against COVID19-Infection and Onward Transmission by Variant of Concern and Time Since Vaccination, Belgian Contact Tracing, 2021Preprint

Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000559 · Cited by 4

Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections

Sejdic, A., Hartling, H. J., Holler, J. G., Gjærde, L. K., Lindegaard, B., Dungu, A. M., Gnesin, F., Møller, M. E. E., Teglgaard, R. S., Niemann, C. U., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360843 · Cited by 3

Long-term observation of antibody titers against SARS-CoV-2 following vaccination

Sugiyama, K., Suzuki, C., Aoyama, M., TOYOTA, N., Nakagawa, N., Shozu, M., Nakai, K., & Iwano, K. (2022) · Public Health in Practice · doi:10.1016/j.puhip.2022.100297 · Cited by 3

Modeling the spatio‑temporal spread of COVID‑19 cases, recoveries and deaths and effects of partial and full vaccination coverage in Canada

Momenyan, S., & Torabi, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-21369-z · Cited by 3

COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review

Faizan, U., Nair, L. G., Zerdan, M. B., Jaberi‐Douraki, M., Anwer, F., & Raza, S. (2023) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355231190497 · Cited by 3

Duration of protective immunity following COVID‐19 vaccination of individuals with underlying health conditions: A rapid review

Walsh, K. A., O’Donnell, H., O’Loughlin, M., Eames, H., Jiang, J., O’Brien, K. M., Broderick, N., O’Brien, K. K., Carrigan, M., Comber, L., et al. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2504 · Cited by 3

Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

Sieghart, D., Hana, C. A., Dürrschmid, C., Heinz, L. X., Haslacher, H., Zlesak, M., Piccini, G., Manenti, A., Montomoli, E., Jorda, A., et al. (2024) · Journal of Clinical Virology · doi:10.1016/j.jcv.2024.105661 · Cited by 3

Metabolic modelling reveals key pathways in COVID-19 in an effort to drive drug purposing

Oliveira, A., Rocha, M., & Dias, Ó. (2024) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2024.10.016 · Cited by 2

Silent SARS-CoV-2 Infections, Waning Immunity, Serology Testing, and COVID-19 Vaccination: A Perspective

Narasimhan, M., Mahimainathan, L., Noh, J., & Muthukumar, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730404 · Cited by 3

To Boost or Not to Boost: Acceptability of a COVID-19 Booster Dose among Osteopathic Medical Students: A Cross-Sectional Study from a Medical School in New York

Janabi, T. A., & Pino, M. A. (2022) · Epidemiologia · doi:10.3390/epidemiologia3020017 · Cited by 3

A severe presentation of breakthrough infection caused by the Omicron variant with radiological findings of COVID-19 pneumonia in an elderly woman

Brogna, B., Capasso, C., Fontanella, G., & Bignardi, E. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.06.034 · Cited by 4

Detection of SARS-CoV-2 Neutralizing Antibodies in Vaccinated Pregnant Women and Neonates by Using a Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader

Chen, W., Lin, Y.-P., Cheng, C., Shen, C., Li, C., Wang, Y., Shih, T., Hong, C., Chang, T., & Shen, C. (2022) · Biosensors · doi:10.3390/bios12100891 · Cited by 3

Risk factors for critical forms of SARS-CoV-2 infection in fully vaccinated patients: a prospective observational study

Bou-ouhrich, Y., & Charra, B. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.43.124.32265 · Cited by 3

Genomic monitoring unveils a high prevalence of severe acute respiratory syndrome coronavirus 2 Omicron variant in vaccine breakthrough cases in Bahia, Brazil

Campos, G. S., Giovanetti, M., de Moraes, L. E. P., da Hora, H. S., Bandeira, A. C., Alcantara, K. V. O. M. D., & Sardi, S. I. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20220955 · Cited by 4

The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis

Stoddard, M., Yuan, L., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2025) · Vaccines · doi:10.3390/vaccines13040368 · Cited by 8

Monocyte-eosinophil signaling axis promotes vaccine-mediated protection against SARS-CoV-2

Moore, K. M., Foster, S. L., Kar, M., Floyd, K. A., Elrod, E. J., Williams, M. E. K., Velden, J. W. V., Ellis, M. L., Malik, A. A., Wali, B., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013752 · Cited by 2

Six‐month longitudinal antibody kinetics of mRNA COVID‐19 vaccines

Suresh, L. (2021) · Rheumatology & autoimmunity · doi:10.1002/rai2.12005 · Cited by 2

Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients

Fujieda, K., Tanaka, A., Kikuchi, R., Takai, N., Saito, S., Yasuda, Y., Fujita, T., Kato, M., Furuhashi, K., & Maruyama, S. (2023) · Vaccines · doi:10.3390/vaccines11010134 · Cited by 2

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in AdolescentsPreprint

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · medRxiv · doi:10.1101/2022.01.04.22268776 · Cited by 16

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac315 · Cited by 22

P-2061. Long-term Follow Up of Pfizer-BioNTech BNT162b2 mRNA Vaccinations Reveals Persistent Disparities between SARS-CoV-2 Naive and Infected Individuals in the Context of Breakthrough Infections

Marklund, E., Lundgren, A., Bemark, M., Nyström, K., Li, Y., Yilmaz, A., Andersson, L., & Gisslén, M. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae631.2217

Long-Term Comparative Effectiveness of BNT162b2 Vaccine on SARS-CoV-2 Infection in Adolescents. A Register-Based Real-World Study from DenmarkPreprint

Cajar, M. D., Andersen, M. P., Krogager, M. L., Schou, M., Kragholm, K. H., Fosbøl, E. L., Køber, L., & Torp-Pedersen, C. T. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4399760